Inventor · disambiguated record
Jason Cross
Also filed as: CROSS JASON · CROSS JASON B · CROSS JASON BRYANT
36 granted patents·15 pending applications·126 citations·filing 2013–2025
96Inventor score
Top patents by PatentIndex Score
51 records- 0195US10954243B2Substituted heterocyclic inhibitors of PTPN11NAVIRE PHARMA INC·Filed 2019·Granted Mar 23, 2021·35 cites·18 claims
- 0295US10280171B2Heterocyclic inhibitors of PTPN11UNIV TEXAS·Filed 2017·Granted May 7, 2019·24 cites·37 claims
- 0394US12186324B2Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2021·Granted Jan 7, 2025·3 cites·26 claims
- 0492US10392376B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Aug 27, 2019·7 cites·32 claims
- 0591US11690850B2Inhibitors of receptor interacting protein kinase I for the treatment of diseaseUNIV TEXAS·Filed 2020·Granted Jul 4, 2023·3 cites·24 claims
- 0689US11058688B2Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2019·Granted Jul 13, 2021·3 cites·41 claims
- 0789US10421765B2Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Sep 24, 2019·7 cites·39 claims
- 0888US8962843B21,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2013·Granted Feb 24, 2015·3 cites·5 claims
- 0987US11104675B2PTPN11 inhibitorsNAVIRE PHARMA INC·Filed 2019·Granted Aug 31, 2021·6 cites·24 claims
- 1086US10800769B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2019·Granted Oct 13, 2020·2 cites·16 claims
- 1186US8916709B21,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitorsCUBIST PHARM INC·Filed 2013·Granted Dec 23, 2014·4 cites·20 claims
- 1285US10899769B2Imidazopiperazinone inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2019·Granted Jan 26, 2021·3 cites·26 claims
- 1385US10093664B2Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of diseaseUNIV TEXAS·Filed 2017·Granted Oct 9, 2018·4 cites·24 claims
- 1484US10851110B2Heterocyclic inhibitors of PTPN11UNIV TEXAS·Filed 2019·Granted Dec 1, 2020·4 cites·20 claims
- 1584US10745420B2Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinaseUNIV TEXAS·Filed 2019·Granted Aug 18, 2020·2 cites·26 claims
- 1683US11560366B2Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of diseaseUNIV TEXAS·Filed 2020·Granted Jan 24, 2023·1 cites·24 claims
- 1783US8969570B2Beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2013·Granted Mar 3, 2015·3 cites·15 claims
- 1882US8940897B21,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitorsCUBIST PHARM INC·Filed 2013·Granted Jan 27, 2015·1 cites·5 claims
- 1982US8933233B21,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitorsCUBIST PHARM INC·Filed 2013·Granted Jan 13, 2015·1 cites·5 claims
- 2082US8933232B21,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2013·Granted Jan 13, 2015·1 cites·5 claims
- 2182US8927724B2Isoxazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2013·Granted Jan 6, 2015·3 cites·39 claims
- 2281US11753381B2Inhibitors of receptor interacting protein kinase I for the treatment of diseaseUNIV TEXAS·Filed 2020·Granted Sep 12, 2023·1 cites·8 claims
- 2381US8962844B21,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitorsCUBIST PHARM INC·Filed 2013·Granted Feb 24, 2015·1 cites·5 claims
- 2480US11718612B2Inhibitors of receptor interacting protein kinase I for the treatment of diseaseUNIV TEXAS·Filed 2020·Granted Aug 8, 2023·1 cites·10 claims
- 2580US2025127792A1Imidazopiperazine inhibitors of transcription activating proteinsUNIV TEXAS·Filed 2024·Application pending·0 cites
- 2680US2025188074A1Ptpn11 inhibitorsNAVIRE PHARMA INC·Filed 2024·Application pending·0 cites
- 2776US12286406B2Inhibitors of receptor interacting protein kinase I for the treatment of diseaseUNIV TEXAS·Filed 2023·Granted Apr 29, 2025·0 cites·20 claims
- 2876US10800774B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2018·Granted Oct 13, 2020·2 cites·25 claims
- 2975US10428057B2Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of diseaseUNIV TEXAS·Filed 2018·Granted Oct 1, 2019·1 cites·46 claims
- 3074US11945815B2PTPN11 inhibitorsNAVIRE PHARMA INC·Filed 2021·Granted Apr 2, 2024·0 cites·16 claims
- 3174US11840536B2Heterocyclic inhibitors of PTPN11UNIV TEXAS·Filed 2022·Granted Dec 12, 2023·0 cites·18 claims
- 3272US2015031659A11,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Application pending·0 cites
- 3372US2022267311A1Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of diseaseUNIV TEXAS·Filed 2022·Application pending·0 cites
- 3468US2015031665A11,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Application pending·0 cites
- 3568US2025214942A1Inhibitors of receptor interacting protein kinase i for the treatment of diseaseUNIV TEXAS·Filed 2025·Application pending·0 cites
- 3667US11434233B2Heterocyclic inhibitors of ATR kinaseUNIV TEXAS·Filed 2020·Granted Sep 6, 2022·0 cites·21 claims
- 3767US2015031666A11,2,4-oxadiazole and 1,2,4-thiadiazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Application pending·0 cites
- 3867US2015038478A1Beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Application pending·0 cites
- 3966US9108966B2Beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Granted Aug 18, 2015·0 cites·3 claims
- 4065US2014323459A1Isoxazole beta-lactamase inhibitorsCALIXA THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4164US2015031660A11,2,4-oxadiazole and 1,2,4-thiadiazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Application pending·0 cites
- 4261US11932643B2Substituted heterocyclic inhibitors of PTPN11NAVIRE PHARMA INC·Filed 2021·Granted Mar 19, 2024·0 cites·21 claims
- 4357US2015038479A1Isoxazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Application pending·0 cites
- 4454US2015038482A1Isoxazole beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Application pending·0 cites
- 4552US11466017B2Heterocyclic inhibitors of PTPN11UNIV TEXAS·Filed 2020·Granted Oct 11, 2022·0 cites·20 claims
- 4649US11365189B2Heterocyclic inhibitors of tyrosine kinaseUNIV TEXAS·Filed 2020·Granted Jun 21, 2022·0 cites·30 claims
- 4748US11046649B2Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenaseUNIV TEXAS·Filed 2019·Granted Jun 29, 2021·0 cites·23 claims
- 4847US2014315876A1Beta-lactamase inhibitorsCUBIST PHARM INC·Filed 2014·Application pending·0 cites
- 4946US2022194940A1Heterocyclic inhibitors of tyrosine kinaseUNIV TEXAS·Filed 2020·Application pending·0 cites
- 5042US11173145B2Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenaseUNIV TEXAS·Filed 2018·Granted Nov 16, 2021·0 cites·27 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jason Cross files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →